Summary of epidemiology, testing and mortality rate; Canada and world statistics.
In the past few years, considerable attention has focussed on the role of B cells in the pathophysiology of multiple sclerosis, in large part because of the success of anti-CD20 monoclonal antibodies (e.g. rituximab, ocrelizumab) in reducing clinical and radiological disease activity. A novel agent, ofatumumab, is expected soon and other agents (e.g. ublituximab) are in development. Read More
The following is a summary of some of the key studies on cognitive dysfunction in multiple sclerosis presented at this year’s European Academy of Neurology virtual congress.
A number of recent studies have provided important insights on the pathophysiology, clinical course and treatment of secondary-progressive multiple sclerosis (SPMS). SPMS is generally characterized as a progressive accumulation of disability after an initial relapsing course; further modifiers are active disease (relapses and/or new MRI lesions) with or without progression, not active with progression and not active and no progression (stable disease) (Lublin et al. Neurology 2014;83:278-286).